1. Home
  2. NEO vs ADNT Comparison

NEO vs ADNT Comparison

Compare NEO & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEO
  • ADNT
  • Stock Information
  • Founded
  • NEO 2001
  • ADNT 2016
  • Country
  • NEO United States
  • ADNT Ireland
  • Employees
  • NEO N/A
  • ADNT N/A
  • Industry
  • NEO Precision Instruments
  • ADNT Auto Parts:O.E.M.
  • Sector
  • NEO Health Care
  • ADNT Consumer Discretionary
  • Exchange
  • NEO Nasdaq
  • ADNT Nasdaq
  • Market Cap
  • NEO 1.2B
  • ADNT 1.4B
  • IPO Year
  • NEO 1999
  • ADNT N/A
  • Fundamental
  • Price
  • NEO $9.62
  • ADNT $12.81
  • Analyst Decision
  • NEO Strong Buy
  • ADNT Hold
  • Analyst Count
  • NEO 10
  • ADNT 9
  • Target Price
  • NEO $19.78
  • ADNT $20.88
  • AVG Volume (30 Days)
  • NEO 1.5M
  • ADNT 2.3M
  • Earning Date
  • NEO 04-29-2025
  • ADNT 05-02-2025
  • Dividend Yield
  • NEO N/A
  • ADNT N/A
  • EPS Growth
  • NEO N/A
  • ADNT N/A
  • EPS
  • NEO N/A
  • ADNT N/A
  • Revenue
  • NEO $660,566,000.00
  • ADNT $14,523,000,000.00
  • Revenue This Year
  • NEO $12.89
  • ADNT N/A
  • Revenue Next Year
  • NEO $11.36
  • ADNT $1.57
  • P/E Ratio
  • NEO N/A
  • ADNT N/A
  • Revenue Growth
  • NEO 11.65
  • ADNT N/A
  • 52 Week Low
  • NEO $8.98
  • ADNT $12.55
  • 52 Week High
  • NEO $19.11
  • ADNT $32.79
  • Technical
  • Relative Strength Index (RSI)
  • NEO 41.15
  • ADNT 33.57
  • Support Level
  • NEO $9.57
  • ADNT $13.34
  • Resistance Level
  • NEO $10.37
  • ADNT $15.14
  • Average True Range (ATR)
  • NEO 0.65
  • ADNT 0.74
  • MACD
  • NEO 0.13
  • ADNT 0.01
  • Stochastic Oscillator
  • NEO 31.79
  • ADNT 10.04

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion.

Share on Social Networks: